

Futura Medical

Raising £12m through £10m placing and £2m retail offer

17 May 2021

- Futura Medical announced on Friday afternoon its intention to raise £10m (gross) through an institutional placing at 40p per share, representing a 20.6% discount to the previous closing price. Part of the placing is directed to VCT ([Venture Capital Trusts](#)), with the shares being deemed eligible and a qualifying holding for the purposes of VCT tax benefits. The new shares are expected to trade from 8am on June 3.
- A retail offer of up to £2m (gross), also at 40p per share, was made available through the PrimaryBid platform. This appears to have been rapidly over-subscribed and closed earlier than the 9pm deadline.
- Use of proceeds is described as four key activities. The principal one is funding FM71, the FDA confirmatory study required for approval of MED3000 as a *de novo* medical device. The study is similar in format to the earlier FM57 trial, but will recruit c 100 patients, including 20 African Americans, with a mix of mild, moderate, and severe erectile dysfunction (ED). FM71 will last six months (24 weeks) and is expected to start in late-2021. Management confirmed this study will cost around £3m (we had expected £2.5m to £3.2m).
- Proceeds will also be directed towards a non-clinical Human Factors Study, to support the anticipated US OTC label; scale-up and manufacturing activities for expected European and other market launches; central support for commercial out-licensing; and general working capital beyond FDA approval and US launch.
- A fifth pre-submission meeting with the FDA is planned for H221 to define and confirm the details of the OTC application. The specifics and scope of FM71, our understanding of FDA requirements, and likely patent position were covered in our [April 2021 Update](#) note. Our assumptions for MED3000 were detailed in our [June 2020 Outlook](#) report.

Price	44.0p
Market Cap	£113.1m
Primary exchange	AIM
Sector	Healthcare
Company Code	FUM
Corporate client	Yes

Company description:

Futura Medical is an R&D driven small pharma company, with a novel DermaSys transdermal delivery platform. The lead programme, MED3000, is a topically applied gel being developed for erectile dysfunction (ED).

Trinity Delta view: The MED3000 CE Mark, received on April 30, effectively removed regulatory risk for the European markets (plus other geographies that recognise the CE Mark). In these regions, the emphasis switches to commercial execution, with a number of agreements addressing these regions expected to be struck in the coming six months. The US regulatory risks remain, albeit reduced following extensive discussions with the FDA. Pending the outcome of the placing we suspend our valuation and forecasts. Our previous valuation was £190.3m, equivalent to 74.3p per share.

Analysts

Lala Gregorek
lgregorek@trinitydelta.org
 +44 (0) 20 3637 5043

Franc Gregori
fgregori@trinitydelta.org
 +44 (0) 20 3637 5041

Lala Gregorek

lgregorek@trinitydelta.org
+44 (0) 20 3637 5043

Franc Gregori

fgregori@trinitydelta.org
+44 (0) 20 3637 5041

Disclaimer

Trinity Delta Research Limited ("TDRL"; firm reference number: 725161), which trades as Trinity Delta, is an appointed representative of Equity Development Limited ("ED"). The contents of this report, which has been prepared by and is the sole responsibility of TDRL, have been reviewed, but not independently verified, by ED which is authorised and regulated by the FCA, and whose reference number is 185325.

ED is acting for TDRL and not for any other person and will not be responsible for providing the protections provided to clients of TDRL nor for advising any other person in connection with the contents of this report and, except to the extent required by applicable law, including the rules of the FCA, owes no duty of care to any other such person. No reliance may be placed on ED for advice or recommendations with respect to the contents of this report and, to the extent it may do so under applicable law, ED makes no representation or warranty to the persons reading this report with regards to the information contained in it.

In the preparation of this report TDRL has used publicly available sources and taken reasonable efforts to ensure that the facts stated herein are clear, fair and not misleading, but make no guarantee or warranty as to the accuracy or completeness of the information or opinions contained herein, nor to provide updates should fresh information become available or opinions change.

Any person who is not a relevant person under section of Section 21(2) of the Financial Services & Markets Act 2000 of the United Kingdom should not act or rely on this document or any of its contents. Research on its client companies produced by TDRL is normally commissioned and paid for by those companies themselves ('issuer financed research') and as such is not deemed to be independent, as defined by the FCA, but is 'objective' in that the authors are stating their own opinions. The report should be considered a marketing communication for purposes of the FCA rules. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and it is not subject to any prohibition on dealing ahead of the dissemination of investment research. TDRL does not hold any positions in any of the companies mentioned in the report, although directors, employees or consultants of TDRL may hold positions in the companies mentioned. TDRL does impose restrictions on personal dealings. TDRL might also provide services to companies mentioned or solicit business from them.

This report is being provided to relevant persons to provide background information about the subject matter of the note. This document does not constitute, nor form part of, and should not be construed as, any offer for sale or purchase of (or solicitation of, or invitation to make any offer to buy or sell) any Securities (which may rise and fall in value). Nor shall it, or any part of it, form the basis of, or be relied on in connection with, any contract or commitment whatsoever. The information that we provide is not intended to be, and should not in any manner whatsoever be, construed as personalised advice. Self-certification by investors can be completed free of charge at www.fisma.org. TDRL, its affiliates, officers, directors and employees, and ED will not be liable for any loss or damage arising from any use of this document, to the maximum extent that the law permits.

Copyright 2021 Trinity Delta Research Limited. All rights reserved.

More information is available on our website: www.trinitydelta.org